Welcome to our dedicated page for Benitec Biopharm news (Ticker: BNTC), a resource for investors and traders seeking the latest updates and insights on Benitec Biopharm stock.
Benitec Biopharma Inc. (NASDAQ: BNTC) is a clinical-stage, gene therapy-focused biotechnology company developing novel genetic medicines based on its proprietary Silence and Replace DNA-directed RNA interference (ddRNAi) platform. News related to Benitec centers on the progress of its lead program, BB-301, a Silence and Replace-based gene therapy candidate in clinical development for dysphagia associated with Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life‑threatening genetic disorder.
Investors following BNTC news can expect detailed updates on clinical trial milestones from the ongoing Phase 1b/2a study of BB-301 (NCT06185673). Company press releases have highlighted interim data showing that all six patients in Cohort 1 met formal statistical criteria for response, with significant and sustained improvements across multiple measures of swallowing function and dysphagic symptom burden. Longer-term follow-up reports describe durable and deepening improvements at 24 months post-treatment for the first treated patient.
Benitec’s news flow also includes regulatory developments, such as the FDA’s Fast Track Designation for BB-301 and Orphan Drug Designations from both the FDA and EMA, as well as updates on interactions with the FDA regarding pivotal study design. In addition, the company regularly reports financial results in Forms 10‑Q and 10‑K, accompanied by press releases that discuss research and development spending, cash position, and capital-raising activities, including underwritten offerings and registered direct offerings of common stock.
Corporate governance and leadership items, such as the appointment of new board members with biotechnology and pharmaceutical experience, are also disclosed through Benitec’s news releases and related Form 8‑K filings. For investors and observers, the BNTC news page provides a centralized view of clinical data updates, regulatory designations, financing transactions, and corporate developments that shape the company’s progress as a clinical-stage gene therapy developer.
Benitec Biopharma (NASDAQ: BNTC) has reported positive interim clinical results from its Phase 1b/2a study of BB-301 gene therapy for Oculopharyngeal Muscular Dystrophy (OPMD). Three subjects treated with BB-301 showed significant improvements in swallowing function:
- Subject 1 achieved durable improvements 12 months post-treatment with 37% reduction for thin liquid, 18% for solid food, and 29% for thick liquids in swallowing efficiency
- Subject 2 reached a clinically normal swallowing profile at 12 months with 91% symptom reduction
- Subject 3 achieved a clinically normal swallowing profile at 3 months with 68% symptom reduction
The study has treated five subjects safely with the low-dose BB-301, with the sixth and final subject of Cohort 1 expected to receive treatment in Q2 2025. No severe adverse events have been reported. Results will be presented at the 2025 Muscular Dystrophy Association Conference in Dallas.
Benitec Biopharma (NASDAQ: BNTC), a clinical-stage biotechnology company specializing in gene therapy and 'Silence and Replace' DNA-directed RNA interference (ddRNAi) platform, has announced its participation in three major healthcare conferences in March 2025.
The company will present at:
- TD Cowen 45th Annual Health Care Conference on March 5, 2025 (9:50-10:20 AM EST)
- Leerink Partners Global Healthcare Conference on March 12, 2025 (9:20-9:50 AM EST)
- 2025 Muscular Dystrophy Association Clinical & Scientific Conference in Dallas, TX, featuring two sessions on March 18-19, 2025, focusing on Oculopharyngeal Muscular Dystrophy and Clinical Trial Updates
All presentations will be available via live webcast, and one-on-one meetings can be scheduled with management.
Benitec Biopharma (NASDAQ: BNTC) has released its Q2 2025 financial results and provided updates on its BB-301 Phase 1b/2a clinical trial for Oculopharyngeal Muscular Dystrophy (OPMD). The fifth subject was safely treated in February 2025, with interim results showing durable, clinically meaningful improvements in swallowing function for the first subjects treated.
Financial highlights for Q2 2025 include:
- Revenue: $0.0 million
- Total expenses: $8.6 million (up from $6.9 million in Q2 2024)
- Net loss: $7.4 million, or ($0.33) per share
- Cash position: $78.3 million as of December 31, 2024
The company plans to begin treating a second cohort with a higher dose of BB-301 later in the year. An interim clinical study update will be presented at the 2025 Muscular Dystrophy Association Conference on March 19, 2025.
Benitec Biopharma (NASDAQ: BNTC) announced the acceptance of a late-breaking oral abstract for their BB-301 Phase 1b/2a Clinical Treatment Study at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference. The presentation, scheduled for March 19, 2025, will provide interim updates on the first three subjects treated with BB-301 for Oculopharyngeal Muscular Dystrophy (OPMD) with moderate dysphagia.
The company previously reported in October 2024 that the first two subjects showed durable, clinically meaningful improvements in swallowing function following BB-301 treatment. The therapy, based on Benitec's proprietary 'Silence and Replace' DNA-directed RNA interference platform, aims to address dysphagia, a severe, life-threatening complication of OPMD. Additional clinical updates for enrolled subjects are planned for Q4 2025.
Benitec Biopharma (NASDAQ: BNTC), a clinical-stage biotechnology company specializing in gene therapy and novel genetic medicines based on their proprietary 'Silence and Replace' DNA-directed RNA interference (ddRNAi) platform, has announced their participation in three upcoming conferences.
The company will attend the Muscular Dystrophy Association Gene Therapy Summit in Tucson, AZ from January 28-30, 2025, followed by the Guggenheim SMID Cap Biotech Conference in New York, NY on February 5, 2025, which will feature one-on-one meetings. Additionally, Benitec will present at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025, at 2:00 PM EST, offering both a presentation and one-on-one meeting opportunities. The Oppenheimer presentation will be available via live webcast.
Benitec Biopharma (NASDAQ: BNTC), a clinical-stage biotechnology company focused on gene therapy and developing genetic medicines using their proprietary 'Silence and Replace' DNA-directed RNA interference platform, has announced their participation in two upcoming investor conferences in December 2024.
The company will participate in the Piper Sandler Annual Healthcare Conference on December 4, 2024, at 12:00 PM EST in New York, featuring a fireside discussion and one-on-one meetings. Additionally, they will attend the Oppenheimer Movers in Rare Disease Summit on December 12, 2024, from 9:50-10:40 AM EST in New York, participating in a panel discussion and one-on-one meetings.
Benitec Biopharma (NASDAQ: BNTC) has released its Q1 2025 financial results and operational updates. The company reported positive interim clinical study data for BB-301 in treating Oculopharyngeal Muscular Dystrophy (OPMD). The first subject showed 35-40% improvement in dysphagic symptoms at 270 days, while the second subject achieved a clinically normal swallowing profile at 180 days. A third subject was treated in October 2024, with a fourth expected in December.
Financial results show no revenue for Q1 2025, with total expenses of $5.8 million. The company reported a net loss of $5.1 million ($0.48 per share) and held $67.8 million in cash as of September 30, 2024.
Benitec Biopharma (NASDAQ: BNTC), a clinical-stage biotechnology company focused on gene therapy and developing genetic medicines using their proprietary 'Silence and Replace' DNA-directed RNA interference (ddRNAi) platform, has announced their participation in the Guggenheim Securities Healthcare Conference. CEO Jerel A. Banks, M.D., Ph.D., will present at the conference on November 11, 2024, at 2:30 PM in Boston. The presentation will be conducted in a fireside chat format with opportunities for one-on-one meetings, and will be available via live webcast.
Benitec Biopharma Inc. (NASDAQ: BNTC) has announced updated investor webcast information for their BB-301 Phase 1b/2a Clinical Study update. The webcast is scheduled for October 14th at 8:30 am EDT, replacing the previously announced conference call information from October 12th.
The live webcast will feature a presentation of interim clinical study data, including insights from management and Dr. Emily Plowman, Professor at The Ohio State University College of Medicine. Investors can access the webcast through a provided link, and a replay along with presentation slides will be available on the company's website afterward.
Benitec Biopharma is a clinical-stage biotechnology company focused on developing novel genetic medicines using their proprietary 'Silence and Replace' DNA-directed RNA interference (ddRNAi) platform.
Benitec Biopharma (NASDAQ: BNTC) reported positive interim data from its Phase 1b/2a study of BB-301 for Oculopharyngeal Muscular Dystrophy (OPMD). Two subjects treated with the low-dose BB-301 showed durable, clinically meaningful improvements in swallowing at 9 and 6 months post-treatment, respectively.
Key findings include:
- No Significant Adverse Events reported
- Subject 1 experienced a 35% reduction in Sydney Swallow Questionnaire (SSQ) Total Score and significant improvements in videofluoroscopic swallowing study (VFSS) assessments
- Subject 2 achieved an 89% reduction in SSQ Total Score, reaching a clinically normal swallowing profile
- Strong correlation between SSQ scores and VFSS Total Pharyngeal Residue results
These results represent the first reported successful improvements in swallow function using a novel gene therapy for OPMD. Benitec plans to treat a third subject with the low dose and enroll additional subjects at higher doses in 2025.
FAQ
What is the current stock price of Benitec Biopharm (BNTC)?
What is the market cap of Benitec Biopharm (BNTC)?
